Inhibrx Biosciences

Research only

INBX · Tracked drugs and regulatory events

Tracked programs

1 program

unresectable or metastatic conventional chondrosarcoma

Publication and retrieval dates are shown separately. Market rules determine which evidence can resolve an outcome.

sec-filingwww.sec.gov

Filing reports BLA acceptance for ozekibart in conventional chondrosarcoma and an April 14, 2027 FDA target.

Sponsor describes ozekibart as a tetravalent DR5 agonist antibody and identifies the ChonDRAgon registrational study.

Registry identifies the associated compound, condition and sponsor; trial completion is separate from FDA action.